» Articles » PMID: 36568197

Immune Subtype Identification and Multi-layer Perceptron Classifier Construction for Breast Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 26
PMID 36568197
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Breast cancer is a heterogeneous tumor. Tumor microenvironment (TME) has an important effect on the proliferation, metastasis, treatment, and prognosis of breast cancer.

Methods: In this study, we calculated the relative proportion of tumor infiltrating immune cells (TIICs) in the breast cancer TME, and used the consensus clustering algorithm to cluster the breast cancer subtypes. We also developed a multi-layer perceptron (MLP) classifier based on a deep learning framework to detect breast cancer subtypes, which 70% of the breast cancer research cohort was used for the model training and 30% for validation.

Results: By performing the K-means clustering algorithm, the research cohort was clustered into two subtypes. The Kaplan-Meier survival estimate analysis showed significant differences in the overall survival (OS) between the two identified subtypes. Estimating the difference in the relative proportion of TIICs showed that the two subtypes had significant differences in multiple immune cells, such as CD8, CD4, and regulatory T cells. Further, the expression level of immune checkpoint molecules (PDL1, CTLA4, LAG3, TIGIT, CD27, IDO1, ICOS) and tumor mutational burden (TMB) also showed significant differences between the two subtypes, indicating the clinical value of the two subtypes. Finally, we identified a 38-gene signature and developed a multilayer perceptron (MLP) classifier that combined multi-gene signature to identify breast cancer subtypes. The results showed that the classifier had an accuracy rate of 93.56% and can be robustly used for the breast cancer subtype diagnosis.

Conclusion: Identification of breast cancer subtypes based on the immune signature in the tumor microenvironment can assist clinicians to effectively and accurately assess the progression of breast cancer and formulate different treatment strategies for different subtypes.

Citing Articles

Tumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategies.

Cao Q, Li C, Li Y, Kong X, Wang S, Ma J Discov Oncol. 2025; 16(1):238.

PMID: 40000527 PMC: 11861463. DOI: 10.1007/s12672-025-01981-x.


A Risk Model Based on Ferroptosis-Related Genes OSMR, G0S2, IGFBP6, IGHG2, and FMOD Predicts Prognosis in Glioblastoma Multiforme.

Wu Y, Liu L, Li Z, Zhang T, Wang Q, Cheng M CNS Neurosci Ther. 2025; 31(1):e70161.

PMID: 39815665 PMC: 11735466. DOI: 10.1111/cns.70161.


Machine learning-guided differential gene expression analysis identifies a highly-connected seven-gene cluster in triple-negative breast cancer.

Ghazal H, El-Absawy E, Ead W, Hasan M Biomedicine (Taipei). 2025; 14(4):15-35.

PMID: 39777114 PMC: 11703398. DOI: 10.37796/2211-8039.1467.


Comparative Evaluation of Machine Learning Models for Subtyping Triple-Negative Breast Cancer: A Deep Learning-Based Multi-Omics Data Integration Approach.

Yang S, Wang Z, Wang C, Li C, Wang B J Cancer. 2024; 15(12):3943-3957.

PMID: 38911381 PMC: 11190774. DOI: 10.7150/jca.93215.


Prediction of cell migration potential on human breast cancer cells treated with Albizia lebbeck ethanolic extract using extreme machine learning.

Umar H, Aliyu M, Usman A, Ghali U, Isah Abba S, Ozsahin D Sci Rep. 2023; 13(1):22242.

PMID: 38097683 PMC: 10721884. DOI: 10.1038/s41598-023-49363-z.


References
1.
Eismann S, Townshend R, Thomas N, Jagota M, Jing B, Dror R . Hierarchical, rotation-equivariant neural networks to select structural models of protein complexes. Proteins. 2020; 89(5):493-501. DOI: 10.1002/prot.26033. View

2.
Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

3.
Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L . Immune infiltration in renal cell carcinoma. Cancer Sci. 2019; 110(5):1564-1572. PMC: 6501001. DOI: 10.1111/cas.13996. View

4.
Jia X, Yan B, Tian X, Liu Q, Jin J, Shi J . CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci. 2021; 17(13):3281-3287. PMC: 8416724. DOI: 10.7150/ijbs.60782. View

5.
Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. DOI: 10.1038/nrc1877. View